Corporate Profile for ThermoGenesis Corp., dated June 18, 1999.
The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: June 18, 1999 Company Name: ThermoGenesis Corp. Address: 3146 Gold Camp Dr. Rancho Cordova, CA 95670 Main Telephone Number: 916/858-5100 Internet Home Page Address (URL) www.thermogenesis.com Chief Executive Officer: Philip H. Coelho Chief Financial Officer: Renee Ruecker, VP Investor Relations Contact: David C. Adams, VP Business number: 916/858-5100 E-mail address: firstname.lastname@example.org Public Relations Contact: David C. Adams, VP Business number: 916/858-5100 E-mail address: email@example.com Industry: Medical device design and manufacture Trading Symbol/ Exchange: Nasdaq:KOOL Market Makers: Paradise Valley Securities; Neidiger, Tucker, Bruner; Fahnestock & Co.; Spear, Leeds & Kellogg; Neuberger & Berman
Company description: ThermoGenesis Corp. ("Company"), founded in 1986, is a leading developer and manufacturer of micro-manufacturing systems designed to harvest Biopharmaceutical drugs from blood.
Biopharmaceutical drugs utilize the body's naturally occurring proteins, enzymes, growth factors, hormones and progenitor cells for the treatment of human disease. ThermoGenesis Corp. Technology Platforms micro-manufacture Biopharmaceutical drugs from a single donation of blood rather than "pools" of blood from thousands of donors or expensive recombinant technology.
The Company believes that micro-manufactured Biopharmaceutical drugs will emerge as the safest, most effective and least expensive treatment for two major medical markets: Wound Care and Cellular Therapy.
The Company's core expertise lies in the areas of thermodynamics and cryopreservation, technologies that it initially applied to ultra rapid freezers and thawers, FDA class I products, sold to blood banks and hospitals in 32 countries throughout the world. Until 4th quarter FY98, the Company's revenues had been principally derived from these core products.
Following four years of intensive research and development, in the 4th quarter of FY98 the Company began shipping its first micro-manufacturing system, the BioArchive(TM) System, a computer controlled liquid nitrogen platform with dedicated disposables for manufacturing and cryopreserving a drug composed of hematopoietic stem and progenitor cells sourced from placental cord blood, which is used to reconstitute the immune system of patients suffering from leukemia, lymphoma, diverse inherited anemias, or hypoproliferative stem cell disorders.
The Company has entered into a period of rapid transformation as it begins the manufacture and marketing of a series of these Biopharmaceutical micro-manufacturing systems with recurring revenues from high margin disposables.
The Company's strategy is to utilize its two new Biopharmaceutical Technology Platforms -- the BioArchive Platform and the CryoSeal(TM) Platform -- as the basis for developing medical devices to micro-manufacture drugs from either autologous or single donor blood which will compete in two major medical markets: Wound Care and Cellular Therapy. -0-
Shares Outstanding: (roughly) 19,764,000 Float: $31 M EPS: $(.48) Long Term Debt: $0.00 Fiscal 1999 High Low First Quarter $2.31 $1.25 Second Quarter $2.69 $0.75 Third Quarter $3.31 $1.75
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 18, 1999|
|Previous Article:||Cameron Announces Senior Management Appointments.|
|Next Article:||Corporate Profile for The Horn Group, dated June 18, 1999.|